Tredu. Expert Education. Smarter Trading.

Mastering Equity and Stock Trading, Cryptocurrency Investment, Digital Assets and Global Forex Market Analysis: The Ultimate Masterclass at Tredu

Gain access to expert-led courses, live market analysis, and educational webinars that turn complex concepts into actionable strategies.Learn how to trade smarter and join our community of successful traders, building sustained financial growth.

Financial News

Maintain market dominance with real-time updates and expert analysis.
Our educators provide focused coverage across stock trading, forex markets, and crypto investing. We translate the latest financial news into practical knowledge, empowering you to trade smarter and achieve superior execution.

Proprietary Trading Strategies and
Quantitative Analysis

Sharpen your execution skills and gain a decisive edge with in-depth insights delivered by our top trading educators. Explore proven trading strategies, anticipate current market trends, and leverage expert analysis specifically designed to support your trading education and accelerate your path to sustained market success.

Tredu Team | Insights

Ionis Pharmaceuticals (NASDAQ:IONS) Stock Plunges on Disappointing Clinical Trial Results

Ionis Pharmaceuticals (NASDAQ:IONS) Stock Plunges on Disappointing Clinical Trial Results

Ionis Pharmaceuticals (NASDAQ:IONS) experienced a significant stock decline following the failure of its drug Wainua in a late-stage clinical trial. Analyst firm Needham reiterated a Buy rating but lowered its price target for Ionis from $105.00 to $86.00. The market reaction saw Ionis shares fall by 23.94%, while competitor Alnylam Pharmaceuticals (NASDAQ:ALNY) saw its stock price increase. Ionis is a leading biotechnology company specializing in the discovery and development of RNA-targeted therapeutics. It aims to treat a wide variety of diseases. The company, with a market capitalization of approximately $10.62 billion, faces competition from firms like Alnylam, which also works in the gene silencing space. Analyst firm Needham reiterates its Buy rating for Ionis, indicating a continued positive outlook on the stock's potential. However, the firm lowered its price target to $86.00 from a previous $105.00. A price target represents an analyst's projection of a stock's future value. The stock was priced at $64.25 when the rating was released. This adjustment follows disappointing clinical trial results. As highlighted by Reuters, Ionis and its partner AstraZeneca (NASDAQ:AZN) announced that their drug Wainua (eplontersen) failed to meet the main goal in a late-stage study. The trial did not show a significant reduction in cardiovascular deaths or recurring heart problems for patients with a specific heart disease. The market reacted strongly to this news. Shares of Ionis fell by 23.94%, a drop of $20.22, to trade at $64.24. The stock saw a very high trading volume of 13.34 million shares, which shows a large number of investors were selling their shares following the announcement from the company. The trial's outcome also affected competitors. As highlighted by Barron's, while shares of Ionis and AstraZeneca declined, the stock price for competitor Alnylam increased. This demonstrates how clinical trial results for one company can directly influence investor sentiment and stock prices for its rivals in the same sector.

Tredu Team | Insights

The Coca-Cola Company (NYSE:KO): A Dividend King's Steady Growth and Analyst Outlook

The Coca-Cola Company (NYSE:KO): A Dividend King's Steady Growth and Analyst Outlook

The Coca-Cola Company (NYSE:KO) is a renowned "Dividend King" and "blue-chip stock," consistently rewarding shareholders with increased dividend payments for 64 consecutive years. Despite hitting an all-time high, an analyst set a conservative price target of $83.00, suggesting limited short-term upside of only 0.65% from its trading price of $82.46 at the time. Strategic acquisitions like Costa Coffee and BODYARMOR, alongside strong performance from products such as Coca-Cola Zero Sugar, are key drivers for the company's sustained long-term growth and financial performance. The Coca-Cola Company is a global beverage corporation known for its wide range of drinks. As a "blue-chip" stock, it is considered a reliable investment from a well-established company. Coca-Cola is also known as a "Dividend King," a title for companies that have increased their dividend payments to shareholders for at least 50 straight years. On July 9, 2026, an analyst from Bernstein set a new price target for Coca-Cola at $83.00. This target was issued when the stock was trading at $82.46. The new price target indicates a potential upside of only 0.65%, suggesting the analyst sees limited short-term growth from its price at that time. This conservative price target comes as shares of Coca-Cola recently hit an all-time high. The company's stock is described as "quietly compounding" over the last decade, as highlighted by 247wallst.com. The stock's current price is $82.54, with a daily trading range between $81.71 and $82.66, showing some recent fluctuation. The company's long-term growth is supported by several strategic moves. These include refranchising its bottling operations and acquiring brands like Costa Coffee in 2019 and BODYARMOR in 2021. A key growth driver is Coca-Cola Zero Sugar, which has seen its sales volume increase by 13% to 14%. Financially, the company reported revenues of $47.94 billion for the 2025 fiscal year. Its status as a Dividend King is confirmed by its 64th consecutive annual dividend increase, as noted by Fool.com. This track record makes it a popular choice for long-term investors seeking consistent returns.

Tredu Team | Insights

3M (NYSE: MMM) Stock Analysis: Wolfe Research Raises Price Target Amid Strong Performance

3M (NYSE: MMM) Stock Analysis: Wolfe Research Raises Price Target Amid Strong Performance

Wolfe Research reaffirmed its Outperform rating for 3M, raising its price target to $189.00 from $182.00. The company's Safety and Industrial segment demonstrated strong performance with a 3.2% year-over-year increase in adjusted organic sales and improved operating margin. 3M projects approximately 3% organic sales growth and an earnings per share (EPS) range of $8.50 to $8.70 for the full year 2026. 3M (NYSE: MMM) is a large, diversified technology company known for its innovation. It operates across several business segments, producing thousands of products. These range from industrial adhesives and personal safety equipment to consumer goods like Post-it Notes and Scotch tape. The company is a major player in the global industrial sector. On July 9, 2026, Wolfe Research confirmed its positive view on 3M with an Outperform rating. The firm also raised its price target to $189.00 from $182.00. A price target is an analyst's projection of a stock's future price. At the time of the rating, the stock was trading at $156.26. This confidence in 3M's investment outlook is supported by strong performance in key areas. As highlighted by Zacks Investment Research, 3M's Safety and Industrial segment saw a 3.2% year-over-year increase in adjusted organic sales in the first quarter of 2026. This growth comes from higher demand for personal safety items and industrial products. The segment's profitability is also improving. Its adjusted operating margin, which measures profit from core operations, grew by 100 basis points due to higher sales volumes and better productivity. The company has an upcoming investor event on July 21, 2026, to discuss its second-quarter results. Looking ahead, 3M projects about 3% organic sales growth for the full year of 2026. The company also expects its earnings per share (EPS), or profit per share of stock, to be in the range of $8.50 to $8.70. This outlook provides a basis for the positive analyst rating and reinforces 3M's financial performance.

Connect with Verified Trading
Educators for Tailored Mentorship
Across All Trading Styles

ADVANCED SEARCH

108 results

Top Brokers

Secure Your Trading Journey with the Right Broker

Advertisement for tredu.com - trading platform

Proud Media Partners of

Cyprus Fintech SummitMoney ExpoGlobal AI Show Abu DhabiGlobal Games ShowForex Expo DubaiGlobal Blockchain ShowEuropean Blockchain ConventionCyprus Fintech SummitMoney ExpoGlobal Games ShowFinancial Innovation ForumGlobal AI Show Abu DhabiForex Expo DubaiGlobal Games ShowCyprus Fintech SummitMoney ExpoGlobal Blockchain ShowEuropean Blockchain ConventionGlobal AI Show Abu DhabiFinancial Innovation ForumForex Expo DubaiGlobal Blockchain ShowCyprus Fintech SummitMoney ExpoEuropean Blockchain ConventionGlobal AI Show Abu DhabiFinancial Innovation ForumCyprus Fintech SummitMoney ExpoGlobal AI Show Abu DhabiGlobal Games ShowForex Expo DubaiGlobal Blockchain ShowEuropean Blockchain ConventionCyprus Fintech SummitMoney ExpoGlobal Games ShowFinancial Innovation ForumGlobal AI Show Abu DhabiForex Expo DubaiGlobal Games ShowCyprus Fintech SummitMoney ExpoGlobal Blockchain ShowEuropean Blockchain ConventionGlobal AI Show Abu DhabiFinancial Innovation ForumForex Expo DubaiGlobal Blockchain ShowCyprus Fintech SummitMoney ExpoEuropean Blockchain ConventionGlobal AI Show Abu DhabiFinancial Innovation Forum